Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-01-01

Reporting Person: FONTEYNE PAUL R. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-01	Stock Option (Right to Buy)	$57.20	A	27600	Acquired	2030-12-31	Common Stock (27600)	Direct

Footnotes

F1: This option was granted on 01/01/2021. The option vests quarterly over 1 year on the last day of each quarter from grant date.